Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u00ae<\/sup> gene targeted chimera small molecules. The company\u2019s GeneTAC\u00ae<\/sup> molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its GeneTAC\u00ae<\/sup> programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington\u2019s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.<\/p>\n
Forward-Looking Statements<\/strong>
Statements in this press release that are not purely historical in nature are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the potential for DT-168 to restore endothelial function and its impact on the treatment of FECD; Design’s ability to advance its pipeline of GeneTAC\u00ae<\/sup> small molecules; and the capabilities and potential advantages of Design\u2019s pipeline of GeneTAC\u00ae<\/sup> small molecules. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cbelieves,\u201d \u201cdesigned to,\u201d \u201canticipates,\u201d \u201ccapable of,\u201d \u201cplans to,\u201d \u201cexpects,\u201d \u201cestimate,\u201d \u201cintends,\u201d \u201cwill,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Design\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the acceptance of INDs by the FDA or similar applications by foreign regulatory agencies for the conduct of planned clinical trials of our product candidates and our proposed design of future clinical trials; nonclinical development activities and results of nonclinical studies; conducting a clinical trial and patient enrollment, which are affected by many factors, and any difficulties or delays encountered with such clinical trial or patient enrollment may delay or otherwise adversely affect Design\u2019s clinical development plans; the process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company; undesirable side effects or other undesirable properties, which could cause Design or regulatory authorities to suspend or discontinue clinical trials and thereby delay or prevent Design\u2019s product candidates\u2019 development or regulatory approval; Design\u2019s ability to develop, initiate or complete nonclinical studies and clinical trials for its product candidates; whether promising early research or clinical trials will demonstrate safety and\/or efficacy in later nonclinical studies or clinical trials; changes in Design\u2019s plans to develop its product candidates; reliance on third parties to successfully conduct clinical trials and nonclinical studies; competitive products, which may make any products we develop or seek to develop obsolete or noncompetitive; Design\u2019s reliance on key third parties, including contract manufacturers and contract research organizations; Design\u2019s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Design\u2019s ability to obtain and maintain intellectual property protection for its product candidates; Design\u2019s ability to recruit and retain key scientific or management personnel; and market conditions. For a more detailed discussion of these and other factors, please refer to Design\u2019s filings with the Securities and Exchange Commission (SEC), including under the \u201cRisk Factors\u201d heading of Design\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 10, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Design undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.<\/p>\n
![](\"https:\/\/ml.globenewswire.com\/media\/ZTAyNTZjYjItZDA0MC00NDEyLWI4YTYtNzAzNTU3N2YxMDY1LTEyMTgzOTItMjAyNS0wNC0yMS1lbg==\/tiny\/Design-Therapeutics-Inc-.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"